Encap has an FDA- and MHRA-inspected development and manufacturing site equipped to handle high potency active ingredients, with an established clinical fast-track program. Encap’s targeted release technologies include DuoCap and ENCODE, and abuse deterrence technologies, Abusolve.
“Encap’s capabilities and offerings align seamlessly with our DFS business unit which is focused on lipid-based formulations and targeted release capsules,” said Guido Driesen, president and chief executive officer of Capsugel. “This acquisition will accelerate the growth of DFS and further strengthen our leadership position in liquid-filled formulations in hard capsules.”
Dr. Stephen Brown, chief executive officer of Encap Drug Delivery, said, “The acquisition by Capsugel will globalize the reach of our products and services. Encap’s focus on liquid-filled technologies has allowed us to develop depth in bioavailability enhancement and drug delivery and we are pleased to join Capsugel, the industry leader in hard capsules and lipid-based dosage form development and manufacturing.”